NCT07362173

Actualities in Procedural Sedation: Remimazolam

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

Remimazolam is a new, ultra-short-acting benzodiazepine approved in Romania for procedural sedation. It shows significant clinical benefits compared to other sedatives like Propofol or Midazolam, especially in elderly or high-risk patients. Advantages include better hemodynamic stability, reduced respiratory depression, lower incidence of postoperative delirium, and rapid recovery without residual sedation. It is metabolized by liver esterases and is less affected by organ dysfunction. Clinical studies suggest that remimazolam may be a safer and more effective alternative in procedural and general anesthesia. The findings support the development of institutional protocols for its use, particularly in high-risk populations and endoscopic procedures.

Conditions

• ASA Class III/IV Patients
• COPD III/IV
• Age 65 and Older
• Multiple Organ Failure

Interventions

Type	Name	Description
DRUG	Administering remimazolam	Administering Remimazolam for procedural sedation
DRUG	Administering propofol	Administering Propofol for procedural sedation

Timeline

• Start date: 2025-03-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2026-01-23
• Last updated: 2026-03-25

Locations

1 site across 1 country: Romania